| Product Unit Size | Cost | Quantity | Stock |
|---|
NVP-BGT226 is an inhibitor of PI3K and mTORC1/2. An intracellular Leishmania parasite assay found it to be even more potent than amphotericin B or miltefosine. In a mouse model of T. brucei acute infection, NVP-BGT226 showed slightly improved effiecacy compared to Torin2.
| Cas No. | 1245537-68-1 |
|---|---|
| Purity | ≥98% |
| Formula | C32H29F3N6O6 |
| Formula Wt. | 650.60 |
| IUPAC Name | (Z)-but-2-enedioic acid;8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one |
| Synonym | BGT226 |
| Solubility | DMSO 30 mg/mL (46.11 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Off-white Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Phan TN, Baek KH, Lee N, et al. In vitro and in vivo activity of mTOR kinase and PI3K inhibitors against Leishmania donovani and Trypanosoma brucei. Molecules. 2020 Apr 23;25(8):1980. PMID: 32340370.
Hassett M, Sternberg A, Roepe P. Inhibition of human class I vs class III phosphatidylinositol 3’-kinases. Biochemistry. 2017 Aug 22;56(33):4326-4334. PMID: 28719179.